Encorium Group Schedules Third Quarter Financial Results and Conference Call
Covalent zu myNews hinzufügen Was ist das?
Encorium Group, Inc. (Nasdaq: ENCO), a leader in the design,
development, and management of complex clinical trials and patient
registries for many of the world's leading pharmaceutical and
biotechnology companies, announced today that it will issue its
financial results for the third quarter of 2007 on Monday, November 12,
2007 after the close of the stock market, with an accompanying
conference call on Tuesday, November 13, 2007 at 11:00 A.M. ET.
To participate in the live call by telephone, please dial (866)
550-5902, or for international callers, please dial (706) 643-2029.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Company’s
Web site at www.encorium.com, or
by clicking the following link:
http://investor.shareholder.com/media/eventdetail.cfm?mediaid=
27939&c=ENCO&mediakey=134C0AABE8B6BF22A36136F295357721&e=0
(Due to its length, this URL may need to be copied/pasted into your
Internet browser's address field. Remove the extra space if one exists.)
Please go to the Web site 15 minutes prior to the scheduled start to
register, download, and install any necessary audio software.
About Encorium Group, Inc.
Encorium Group, Inc. is a global clinical research organization that is
a leader in the design and management of complex clinical trials and
Patient Registries for the pharmaceutical, biotechnology and medical
device industries. The Company’s mission is to
provide its clients with high quality, full-service support for their
biopharmaceutical and medical device development programs. Encorium
offers therapeutic expertise, experienced team management and advanced
technologies. The Company has drug and biologics development as well as
clinical trial experience across a wide variety of therapeutic areas
such as infectious diseases, cardiovascular, vaccines, oncology,
endocrinology/metabolism, diabetes, gene therapy, immunology, neurology,
gastroenterology, dermatology, hepatology, women’s
health and respiratory medicine. Encorium believes that its leadership
in the design of complex clinical trials, its therapeutic expertise and
commitment to excellence, and its application of innovative
technologies, offer its clients a means to more quickly and cost
effectively move products through the clinical development process.
Encorium is headquartered in Wayne, Pennsylvania with its European base
of operations in Espoo, Finland. The Company has a geographic footprint
that includes over one billion people in North America,
Western/Central/Eastern Europe, Scandinavia, and the Baltics.
This press release contains forward-looking statements identified by
words such as "estimate,” "project,” "expect,” "intend,” "believe,” "anticipate” and
similar expressions. Actual results might differ materially from those
projected in, expressed in or implied by the forward-looking statements.
Potential risks and uncertainties that could affect the Company's future
operating results and financial condition include, without limitation:
(i) our success in attracting new business and retaining existing
clients and projects; (ii) the size, duration, and timing of clinical
trials we are currently managing may change unexpectedly; (iii) the
termination, delay or cancellation of clinical trials we are currently
managing could cause revenues to decline unexpectedly; (iv) the timing
difference between our receipt of contract milestone or scheduled
payments and our incurring costs to manage these trials; (v) outsourcing
trends in the pharmaceutical, biotechnology and medical device
industries; (vi) the ability to maintain profit margins in a competitive
marketplace; (vii) our ability to attract and retain qualified
personnel; (viii) the sensitivity of our business to general economic
conditions; (ix) other economic, competitive, governmental and
technological factors affecting our operations, markets, products,
services and prices; (x) announced awards received from existing and
potential customers are not definitive until fully negotiated contracts
are executed by the parties;(xi) our backlog may not be indicative of
future revenues and may not generate the revenues expected;(xii) our
ability to successfully integrate the businesses of Encorium and
Remedium Oy which we acquired on November 1, 2006; and (xiii) ability of
the combined businesses to operate successfully, generate revenue growth
and operating profits. You should not place any undue reliance on these
forward looking statements which speak only as of the date of this press
release. Additional information concerning factors that might affect our
business or stock price which could cause actual results to materially
differ from those in forward-looking statements is contained in Encorium
Group's SEC filings, including its Annual Report on Form 10-K for the
year ended December 31, 2006 and other periodic reports under the
Securities Exchange Act of 1934, as amended, copies of which are
available upon request from Encorium Group's investor relations
department or The Equity Group Inc.
